Known targets — ChEMBL curated mechanism
EGFREPHA1EPHA10EPHA2EPHA3EPHA4EPHA5EPHA6EPHA7EPHA8EPHB1EPHB2EPHB3EPHB4EPHB6ERBB2ERBB3ERBB4FLT1FLT4KDRPTK6RETSRCTEK
The experimentally established mechanism targets of Vandetanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 0.76 |
| ▸ | KDR known ✓ | P35968 | 14/20 | 0.76 |
| ▸ | FLT1 known ✓ | P17948 | 12/20 | 0.76 |
| ▸ | FLT4 known ✓ | P35916 | 12/20 | 0.76 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.76 |
| ▸ | EPHA2 known ✓ | P29317 | 3/20 | 0.76 |
| ▸ | EPHB4 known ✓ | P54760 | 3/20 | 0.76 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.76 |
| ▸ | EPHB6 known ✓ | O15197 | 1/20 | 0.76 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.76 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.76 |
| ▸ | EPHA1 known ✓ | P21709 | 1/20 | 0.76 |
| ▸ | ERBB3 known ✓ | P21860 | 1/20 | 0.76 |
| ▸ | EPHA3 known ✓ | P29320 | 1/20 | 0.76 |
| ▸ | EPHA8 known ✓ | P29322 | 1/20 | 0.76 |
| ▸ | EPHB2 known ✓ | P29323 | 1/20 | 0.76 |
| ▸ | EPHA5 known ✓ | P54756 | 1/20 | 0.76 |
| ▸ | EPHB1 known ✓ | P54762 | 1/20 | 0.76 |
| ▸ | EPHA4 known ✓ | P54764 | 1/20 | 0.76 |
| ▸ | PTK6 known ✓ | Q13882 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vandetanib SCHEMBL1783178 | 0.93 | EGFR (0.89) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4171108 | 0.90 | KDR (0.62) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4025000 | 0.89 | KDR (0.73) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL12604711 | 0.89 | RET (0.84) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1783321 | 0.87 | KDR (0.60) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL1781457 | 0.87 | KDR (0.58) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL29352879 | 0.86 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL28224661 | 0.86 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL9044 | 0.86 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL4637084 | 0.86 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609673-B2 | Vandetanib derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110117084-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2009094210-A1 | VANDETANIB DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117084-A1 | VANDETANIB DERIVATIVES | KDR, VHL, FLT4 | EGFR 17/4885KDR 1/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.